Transdermal Delivery of AT1 Receptor Antagonists Reduce Blood Pressure and Reveal a Vasodilatory Effect on Kidney Blood Vessels by Michalatou, M et al.
1 
 
Transdermal delivery of AT1 receptor antagonists reduce blood pressure and 
reveals a vasodilatory effect in kidney blood vessels. 
 
Michaila Michalatoua,+, Maria Eleni Androutsoub,+, Markos Antonopoulosc, Demetris Vlahakosd, 
George Agelisb, Anthony Zullie, Tawar Qaradakhie, Kathleen Mikkelsene, Vasso 
Apostolopoulose,*,++, John Matsoukasa,b,*,++ 
 
a  Department of Chemistry, University of Patras, Patras, 26500 Greece 
b Eldrug S.A. Patras Science Park, Platani, Patras, 26540 Greece  
c  King’s College London, School of Biomedical and Health Sciences, London, UK 
d  Department of  Internal Medicine, Attikon University Hospital, 12462, Athens, Greece 
e Institute for Health and Sport, Victoria University, Mebourne, VIC 3030 Australia 
 
* Corresponding authors at: (JM) Eldrug S.A., Patras Science Park, Platani, Patras, 26540 
Greece, Email: imats1953@gmail.com and (VA) Institute for Health and Sport, Victoria 
University, Melbourne, VIC 3030 Australia, Email: vasso.apostolopoulos@vu.edu.au  
 
+ equal contribution 
++ equal contribution 
 
 
Running title: Anti-hypertension patch 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
_______________________________________________________________ 
 
Abstract 
 
Background: The Renin Angiotensin System (RAS) is pharmacologically targeted to reduce 
blood pressure, and patient compliance to oral medications is a clinical issue.  The mechanisms 
of action of angiotensin receptor blockers (ARBs) in reducing blood pressure are not well 
understood, and is purported to be via a reduction of angiotensin II signaling.  
Objective: We aimed to develop a transdermal delivery method for ARBs (losartan potassium 
and valsartan) and to determine if ARBs reveal a vasodilatory effect of the novel RAS peptide, 
alamandine. In addition we determined the anti-hypertensive effects of the transdermal delivery 
patch. 
Methods: In vitro and in vivo experiments were performed to develop an appropriate therapeutic 
system, promising an alternative and more effective therapy in the treatment of hypertension. A 
variety of penetration enhancers were selected such as isopropyl myristate, propylene glycol, 
transcutol and dimenthyl sulfoxide to obtain a constant release of drugs through human skin. 
Small resistance vessels (kidney interlobar arteries) were mounted in organ baths and incubated 
with an ARB. Vasodilatory curves to alamandine were constructed 
Results: The in vivo studies demonstrates that systemic absorption of valsartan and losartan 
potassium using the appropriate formulations provides a steady state release and anti-
hypertensive effect even after 24 hours of transdermal administration. No apparent skin 
irritations (erythema, edema) were observed with the tested formulations. We also show that 
blocking the AT1 receptor of rabbit interlobar arteries in vitro reveals a vasodilatory effect of 
alamandine.  
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Conclusion: This study reveals potential mechanism of AT1 receptor blockade via alamandine, 
and is an important contribution in developing a favorable, convenient and painless 
antihypertensive therapy of prolonged duration through transdermal delivery of AT1 blockers. 
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INTRODUCTION 
 Transdermal drug delivery system (TDDS) is a novel approach for administration of 
drugs. They offer several important pharmacological advantages over conventional dosage 
forms, such as avoidance of first-pass metabolism by the liver, minimizing pain, controlled 
release of drug and prolonged duration [1, 2]. Currently, approximately 74 % of drugs are 
administered orally and have reduced efficacy due to first pass metabolism, as well as related 
side effects.  As well, drugs for several diseases such as diabetes (insulin), multiple sclerosis 
(interferons) and cancer (taxol) taken by injections must be administered in a painless and 
effective manner [3]. In this regard,  transdermal delivery of drugs can bypass these issues.  For 
example, new transdermal drugs are used for multiple sclerosis (MBP85-99, MOG35-55 and PLP139-
155) [4]. Thus, TDDS (transmucosal delivery systems) and controlled release systems have 
emerged to overcome disadvantages of the oral or injection route [5].  However, the stratum 
corneum (SC) is a barrier to the absorbtion of such drugs  [6]. The characteristic requirements for 
a drug to be effective is a small molecular size and weight less than 500 Da, significant 
lipophilicity, efficacy in low plasma concentration and high degree of stability [7-9]. To enhance 
transdermal absorption of the active ingredient, drug derivatives, prodrugs, drug saturated 
systems and physical and chemical enhancers that facilitate permeation of the drug through the 
stratum corneum can be used [10, 11].  
 Herein, we used ethanol (EtOH), isopropyl myristate (IPM), propylene glycol (PG), 
transcutol (TCL) and DMSO as CPEs [11-13]. IPM is an ester, well-known to be an effective 
CPE for a wide variety of drugs including indapamide, S-almodipine, isosorbide dinitrate, 
lincomycin hydrochloride and terbutaline sulfate [8]. PG is a common excipient which promotes 
the flux of heparin sodium, verapamil hydrochloride and ketoprofen [11]. The combination of 
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TCL and PG increases clonazepam permeation [14]. DMSO is one of the earliest and most 
widely studied penetration enhancers. It is used to treat severe herpes infections of the skin and 
as a co-solvent in idoxuridine [11, 13]. In addition, nitroglycerine has been used as a patch for angina. 
A sartan as a patch will be beneficial to all RAS based hypertensive patients [15, 16]. The merits of a 
sartan patch is the continuous control of blood pressure, considering that in the morning patients 
appear to have increased hypertension [17]. Blood pressure could be monitored with suitable 
enhancers allowing appropriate sartan penetration and longer duration. In the current study we aimed 
to develop a transdermal delivery method for angiotensin receptor blockers (ARBs, ie. losartan 
potassium and valsartan), their anti-hypertensive properties and to determine whether ARBs 
reveal a vasodilatory effect of the novel RAS peptide, alamandine.  
 Valsartan and losartan potassium were chosen in this study. Valsartan is an orally active 
angiotensin II (ANGII) type 1 receptor blocker (ARB) and is prescribed for the management of 
hypertension. It is a lipophilic drug with low molecular weight (435.519 g/mol), available as a 
white, microcrystalline powder with a melting range of 105-110 °C with low oral bioavailability 
(25 %). The partition coefficient P is 0.033 (log P=1.499), suggesting that the compound is rather 
hydrophilic at physiological pH and half life is approximately 6 hours [18]. Losartan potassium, 
the first selective AT1 blocker, has a low molecular weight (461.01 g/mol), available as white 
crystalline powder with melting point 183-184 °C with low oral bioavailability (33 %). The log P 
is 3.85 [19] and half life is approximately 2.1±0.70 hours [7].  
 Our interest in the effects of small RAS peptides and ANG II receptor antagonists [20-24] 
could be extended to congestive heart failure, as well as for the pathogenesis of diabetes and 
kidney disease [25, 26]. Selective blockade of the AT1 receptor may prevent the known 
pathologic effects of ANG II associated with its stimulation, whilst allowing the positive effects 
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induced by the AT2 receptor [21, 27, 28]. Previously we designed, synthesized and studied 
biological and physicochemical properties of peptides and non peptide mimetics of ANGII [20, 
22, 23, 29, 30]. Furthermore, the reduction of blood pressure observed by ARBs is claimed to be 
due to the reduction in ANGII/AT1R signaling, yet circulating ANGII is increased nearly 5-fold 
[31] and the kidney plays a significant role in hypertension in rat [32].  We propose that blockade 
of the AT1 receptor could reveal other vasodilative effects in the vasculature, by enhancing the 
vasodilatory peptides of RAS, such as alamandine [33, 34] in kidney blood vessels. Alamandine, 
a novel heptapeptide of the RAS, has been demonstrated to enhance acetylcholine (ACh)-
mediated vasodilation in New Zealand white rabbits in vitro [35] and antihypertensive effects in 
spontaneously hypertensive rats after oral administration [36]. 
 
MATERIALS AND METHODS 
Materials  
 Valsartan and losartan potassium were a gift from pharmaceutical company, Vianex SA. 
PG, TCL, IPM, EtOH and phosphate buffer were purchased from Sigma Aldrich (Germany, 
purity > 98 %). HPLC grade water was obtained from distilled water passed through a milli-Q 
water purification system (Millipore Ltd., Bedford, MA, USA). HPLC-grade acetonitrile 
(MeCN) and methanol (MeOH) were purchased from Panreac Química S.A. DMSO and 
trifluoroacetic acid (TFA) were of HPLC analytical grade and were purchased from Scharlau and 
Alfa Aesar respectively. 
 All chemicals for KREBS (118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4 7H2O, 1.2 mM 
KH2PO4, 25 mM NaHCO3 and 11.7 mM glucose), ACh (purity > 99 %), phenylephrine and 
candesartan (purity > 98 %) were purchased from Sigma Aldrich (USA). Alamandine (purity 99 
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%) was purchased from the Mimotopes (Notting Hill, Australia).  
 
Animals 
 Wistar rats (aged 5 months) were purchased from Greek Institute of Pasteur and were 
bred in the animal experimental center of medical department of University of Patras. Animals 
were individually housed and maintained on a 12:12 light:dark cycle (lights on at 7am) at 25 ± 2 
oC with ad libitum access to food and water throughout the experiment. All experimental 
protocols were conducted in accordance with the law of the European convention for the 
protection of animals used for experimental or other research purposes (2010/63/EU) and were 
approved by the institutional animal care and use committee at the school of Medicine, 
University of Patras, Greece (code EL13 BIO 04). Male New Zealand white rabbits (aged 3 
months) were housed in individual cages and maintained at a constant temperature of 21 ºC, 
where food and water were supplied ad libitum. These animals were approved by the Victoria 
University animal ethics committee (VUAEC#03/11) under the guidelines of the National Health 
and Medical Resaerch Council (NHMRC) Australia.  
 
Preparation of human skin 
 Human live skin was collected from unused portion of human female patients from 
General University Hospital of Patras with consent. Subcutaneous adhering fat and connective 
tissues were carefully removed and the excised skin was cut to an appropriate size. Full thickness 
human skins were stored at -20 oC until the day of the experiment.  
 
Preparation of the formulations 
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 Preparation of valsartan formulations V2, V3 and V5 (Table 1): Valsartan (0.625 g) was 
dissolved in EtOH (0.75 g) and the mixture was vortexted for 30 seconds. DMSO (0.125 g) was 
added and the mixture vortexed to achieve a homogenous solution. Additionally, accurately 
weighed quantity of other ingredients: PG (0.75 g), IPM (0.25 g); IPM (0.25 g), TCL (0.75 g); 
PG (0.25 g), IPM (0.75 g) were added into formulations V2, V3 and V5 respectively. A 2-phase 
formulation was produced after the addition of IPM. 
 Preparation of valsartan formulations V1 and V4 (Table 1): Valsartan (0.625 g) was 
dissolved in EtOH (0.625 g) and the mixture was mixed for 30 seconds using a vortex mixer. 
IPM (1.25 g) and PG (1.25 g) were added into V1 and V4 formulations respectively to achieve 
the final formulations. A 2 phase formulation was produced after the addition of IPM. 
 Preparation of losartan formulations L1-L5 (Table 1): Losartan potassium (0.625 g) was 
dissolved in H2O (0.498 g) and the mixture was mixed for 30 seconds using a vortex mixer after 
which EtOH (0.287 g) was added and the mixture mixed to achieve a homogenous solution. 
Additionally accurately weighed quantity of other ingredients: PG (0.125 g), IPM (0.839 g), TCL 
(0.125 g); PG (0.125 g), IPM (0.964 g); IPM (1.089 g); PG (1.089 g); IPM (0.544 g), PG (0.544 
g) were added into formulations L1 - L5 respectively. A 2-phase formulation was produced 
following the addition of IPM. 
 Losartan was used in these studies based on a feasibility report that we conducted that 
suggested that the transdermal delivery of losartan was feasible, and thus it was used over 
telmisartan which is more lipophlic than losartan or candesartan. Estimations were based on 
physicochemical properties of losargan, its overal dose and bioavailability. Moreover, valsartan 
was selected since it had similar molecular weight with losartan, was more potent, with lower 
daily dose, and both sartans were available as generics for further development. 
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 Alamandine is a heptapeptide formed from the removal of the 8th peptide from 
angiotensin A, possibly by ACE2. Alamandine differs from angiotensin (1-7) in the primary 
amino acid, alanine (which contains a methyl group on the amino end), compared to aspartate, 
(which contains a carboxy group), respectively [37]. Extensive simulation and modeling studies 
between the octapeptide ANGII and Losartan, based on SAR and NMR findings, had previously 
shown mimicry of the ANGII critical amino acid side chains (Tyr, Val, His, Phe) and the C-
terminal carboxylate with Losartan’s pharmacophoric groups (-CH2OH, imidazole ring, butyl 
side chain, tetrazole) (Scheme 1a) [38]. Deletion of the Phe residue as in Alamandine, deprives 
the heptapeptide from its agonist property rendering the vasodilatory effects (Scheme 1b). These 
studies show the importance of the Phe aromatic ring at position 8 for agonist hypertensive 
activity. 
 
Instrumentation – Liquid Chromatography  
 All analyses were performed on a Waters Alliance HPLCTM system (Waters 2695 
separation module equipped with waters 2996 photodiode array detector and data acquisition 
empower 2). Chromatographic separation was performed on a XBridgeTM C18 (4.6mm ID*150 
mm length) column with 3.5 μm particle size [39]. Under the described experimental conditions, 
the peak was well defined and free from tailing. 
 
Preparation of standard solutions and quality control samples 
 Freshly prepared stock solutions of valsartan and losartan (1 mg/ml) were prepared by 
dissolving 10 mg of the compound in 10 ml of MeOH and purified H2O, respectively. Nine 
working standard solutions of the analyte at concentrations of 0.1, 0.2, 1, 2, 10, 20, 50, 100 and 
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200 μg/ml were prepared by further dilution of the stock solution with appropriate volumes of 
H2O. Low, medium and high quality control (QC) samples of the analytes at concentrations of 8 
μg/ml, 90 μg/ml and 160 μg/ml were similar and prepared by further dilution of the stock 
solution with appropriate volumes of H2O for the evaluation of the methods.  
 
Preparation of internal standard and calibration model 
 The concentration range of the 2 compounds for the construction of the calibration curves 
was between 0.1 and 200 μg/ml, using the internal standard (IS) method. Losartan potassium (20 
μg/ml) and valsartan (40 μg/ml) were used as IS for valsartan and losartan, respectively.  
 The construction of the calibration curve was based on the analysis of the calibration 
standards (n=4) at the 9 concentration levels ranging from 0.1 to 200 μg/ml and plotting the peak 
area ratios of the analyte to IS against the nominal calibration standard concentration. Three 
different calibration curves (n=3) were prepared during two weeks (Table 2). Linearity was 
evaluated by linear regression analysis, which was calculated by the least-square regression 
analysis. LOD was determined as the sample concentration obtaining a peak area of 3 times the 
noise level and LOQ as the sample concentration obtaining a peak area of 10 times the noise 
level [40] and the lower point of the calibration curve is used for estimating [41]. 
 
Intra- and inter- day precision and accuracy 
 Precision of the analytical method was defined as relative standard deviation (% RSD) 
and was evaluated in terms of intra-day and inter-day precision for four samples (n=4) at 
concentrations of QC samples at three levels (low QC, medium QC and high QC). Accuracy of 
the method was determined by relative error (% RE) [42]. 
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In vitro skin permeability studies 
 A vertical Franz-type glass, jacketed diffusion cell system with a magnetic stirrer and a 
thermostatic water bath was used for the studies [8, 43, 44]. The full-thickness excised human 
skin (bround to room temperature) was mounted on the top of the Franz diffusion cell (vertical 
available diffusion area, 1.77 cm2; volume of receiver cell, 12 ml) and was fastened with a rigid 
clamp. The temperature was maintained at 32 ± 1 oC using a thermostatic water bath. The SC 
side of the skin sample was facing upward into the donor compartment and the dermal side was 
facing downward into the receptor compartment. The receptor compartment was filled with 
phosphate buffered saline (pH 7.4) and stirred by magnetic bar to ensure adequate mixing and 
maintenance of sink conditions. For each experiment, the donor compartment was loaded with 
300 μl of the formulation of the drug to the SC side of the skin. Samples (480 μl) were 
withdrawn every 3, 6, 8, 24, 30 hours and equal volume of blank solution was immediately 
added. Six replicates of each experiment were performed. At the end of the experiment the skin 
remained intact and undamaged. The standard curve was used for estimating the concentration of 
valsartan and losartan in samples using HPLC.  
 
Mechanistic assessment of AT1 receptor blockade in organ bath studies 
 Rabbits were used to assess the mechanism of AT1 receptor blockade due to their 
sensitivity to ANGII blood vessel constriction similar to human arteries [45, 46].  Rabbits were 
killed by exsanguination after anesthesia with 4 % isoflurane,  followed by the extraction of 
interlobar arteries from kidneys (VUAEC#03/11). Interlobar arteries were cleaned of fat and 
connective tissue then cut into 3 mm arterial rings and mounted onto organ baths attached to 
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force displacement transducers in order to measure the response of arterial rings in grams (OB8, 
Zultek Engineering, Melbourne, Australia [47]). The organ baths were filled with KREBS which 
was at a constant temperature of 37 ºC with continuous bubbling of carbogen (95 % O2 and 5 % 
CO2). Phenylephrine (Phen) was used to pre-constrict the arterial rings until a plateau was 
reached. Candesartan (10-5 M) [48, 49] was added for 5 mins prior to the first dose of alamandine 
dose response curve. ACh was added after the final dose of alamandine to indicate functional 
arterial rings. Candesartan was used in organ baths as it has direct effects on renal blood vessels 
[48, 49] as well as being commonly used in animal models of blood pressure studies [48]. 
 
In vivo biological evaluation  
 The time-dependent antihypertensive efficacy of valsartan and losartan potassium 
formulations via transdermal administration in Wistar rats (370 ± 80 g) was evaluated by the 
modulations of the hypertensive response elicited by subcutaneous bolus injections of ANG II 
(50 μg/kg body weight) were recorded in eight Wistar rats (370 ± 80 g) using at 0, 3, 6, 8 and 24 
hours. The mean arterial blood pressure was recorded using a Coda, non-invasive blood presure 
system (Kent Scientific) [50]. Fourty eight hours prior to the treatment, hair from the dorso-
lumbar region at two contralateral sites of each rat was depilated. A volume of 300 μl of V2 
formulation for valsartan (n=6), L1 formulation for losartan (n=6) and placebo (n=2) were 
applied transdermally in a depilated area, of approximately 10 cm2, and a membrane was over it 
to secure the formulation in place and prevent the evaporation of the volatile solvents. In 
addition, the treated site was covered with gauze and secured at the margins to prevent leakage of 
the test substance and to ensure that the rats did not bite and remove the formulation.  
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Data analysis 
 The permeation of valsartan and losartan using different enhancers was assayed for 30 
hours and plots of the cumulative amount of the permeated drug (μg/cm2) through human skin 
were plotted versus time (hours). The transdermal flux (J, μg/cm2*h), the rate of change of the 
cumulative amount of drug passes per unit area and time through the skin, was calculated from 
the steady-state part of the curve. Lag time (Tlag) is obtained by the extrapolation of the linear 
portion to the x-axis [2]. The release data was fitted into various mathematical models using 
software to know which mathematical model will best fit to obtained release profiles. To 
determine the effects of penetration enhancers on the skin permeation of valsartan and losartan 
GraphPad Prism (Version 7, GraphPad Software Inc, USA) was used to perform two-way 
ANOVA (dose vs flux) followed by Tukeys multiple comparisons test to determine significance 
between each group, with p < 0.05 considered significant. For the organ bath procedures, the 
response given in grams was translated into % of response against each cumulative doses of 
alamandine. GraphPad Prism was also used to perform a two-way ANOVA (dose vs response) 
repeated measures followed by a Sidak’s multiple comparisons post hoc test to determine 
significances between doses of alamandine. p < 0.05 was considered a significant.    
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RESULTS 
Method Validation 
 The calibration standard samples analyzed by the developed analytical methodology 
showed that the retention time of valsartan and losartan was 9.43±0.03 min and 4.85±0.03 min, 
respectively. Over the concentration range from 0.1 to 200 μg/ ml regression analysis indicated 
that there was an excellent linearity between UV absorption and valsartan and losartan 
concentrations (Table 2). The limit of quantification (LOQ) of the developed methodology was 
0.1 μg/ml and the limit of detection (LOD) was 0.03 μg/ml. The methods were evaluated in 
terms of intra-day precision and accuracy by assaying (n=3) QC samples at low QC (8 μg/ml), 
medium QC (90 μg/ml) and high QC (160 μg/ml). Table 3 shows the precision and accuracy of 
the analytical method of valsartan and losartan calculated in values of % RSD and % RE. 
 
Effects of penetration enhancers on the skin permeation of valsartan and losartan 
 The effects of CPEs on the permeation of valsartan and losartan from formulations (V1-
V5, L1-L5) through full thickness human skin are summarized in Table 4. It is well known that 
the penetration of a drug through rat skin is considerably greater than that through human skin 
[8]. Therefore, human skin was used to obtain a better estimation of the drug permeation in 
humans. Among all portions, V2 and V1 for valsartan (Fig. 1) with a flux value of J=0.5024 
μg/cm2*h and J=0.3774 μg/cm2*h, respectively (Table 4) and L1 for losartan (Fig. 2) with a flux 
value of J=0.2652 μg/cm2*h (Table 4) had the most conspicuous effect. Accordingly, 
formulation V2 which contained 30 % w/w PG, 10 % w/w IPM and 5 % w/w DMSO showed a 
significant increase of permeation flux within 3 hours (p < 0.0001 V2 compared to V1, p < 0.01 
V2 compared to V3 and p < 0.01 V2 compared to V5) which continued to significantly increase 
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up to 30 hours (p < 0.05 V2 compared to V1, p < 0.0001 V2 compared to V3,  p < 0.0001 V2 
compared to V4, and p < 0.0001 V2 compared to V5) (Fig. 1).  In addition, L1 which contained 
33.57 % w/w IPM, 5 % w/w PG and 5 % w/w TCL showed significant increase of permeation 
flux compared to L2, L3, L4 and L5 within 6 hours and remained significant up to 30 hours (p < 
0.0001) (Fig. 2). It is reported that the purposed formulation containing two or three enhancers 
showed significantly enhanced permeation. Specifically, the addition of PG, IPM and DMSO 
(V2) and the addition of PG, IPΜ and TCL (L1) resulted in a synergistic penetration 
enhancement effect on valsartan and losartan, respectively. In general, enhancers may change the 
structure of the lipids in the SC, denature the skin proteins and changes the properties of the 
horny layer, and as a consequence the SC becomes more permeable for drugs [51-53]. The 
enhancement resulting from the presence of IPM is connected with its increased fluidity in the 
lipids of the skin as well as with the lipid disruption due to high affinity between IPM and the 
components of the skin [8, 51]. 
 
In vivo evaluation studies 
 In order to investigate the in vivo transdermal process of valsartan and losartan, the more 
efficient formulation resulting from the in vitro studies was estimated by the effects of 
antihypertensive evaluation in Wistar rats (Fig 3). Mean arterial blood pressure (MABP) was 
recorded after 3, 6, 8 and 24 hours of subcutaneous bolus injections of ANGII in order to 
evaluate the antihypertensive activity of valsartan and losartan following transdermal delivery to 
the systematic circulation. As shown in Fig. 3, losartan showed a significant decrease in MABP 
by 24 hours (p < 0.00001), however, valsartan was more potent showing significant reduction in 
MABP within 3 hours (p < 0.05) which remained significant at 6, 8 and 24 hours (p < 0.01) 
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following administration. Since there was no observable skin irritation in the animals during the 
study, these 2 transdermal formulations can be  used for further development. 
 
Assessment of AT1 receptor blockade in organ bath studies 
 In order to determine the pathway of which blocking the AT1 receptor exerts vasodilatory 
effects, we conducted a dose response curve to alamandine with candesartan (an active in vitro 
ARB).  The addition of candesartan had no effect on vasoconstriction caused by phenylephrine. 
Alamandine induced direct vasoconstriction on interlobar artery in a dose dependent manner (10-
8 M, 10-7 M and 10-6 M corresponded to 5.4±1.3 %, 12.2±1.9 % and 15.2±0.9 % of constriction, 
respectively). However, candesartan revealed a vasodilatory effect of alamandine in the 
interlobar arteries, to 1±1.7 %, -6.7±3.0 % (p<0.001) and -10.1±5.0 % (p<0.001) (Fig. 4A). Real 
time trace of the experiments are also shown (Fig. 4B). 
 
DISCUSSION 
 In this study, we show that ARBs can be formulated so that they are better absorbed 
through the skin to reduce blood pressure, possibly via a vasodilatory effect of alamandine in 
kidney blood vessels. 
 
In vitro evaluation of Valsartan 
 In this study, a combination of penetration enhancers were used to evaluate the drug 
release of valsartan and losartan potassium. Valsartan is a poorly water - soluble drug with poor 
oral bioavailability (approximately 25%). Permeation enhancers such as IPM, EtOH, DMSO 
improves drug solubility and penetration into the skin. The formulations V1 and V4 constituted 
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of EtOH as main solvent and IPM and PG respectively. The V2 formulation, which contained a 
mixture of these two enhancers showed a significant increase of permeation flux. From the data 
obtained from V3 and V5 formulation, changing the proportions of enhancers (PG and IPM), 
showed less permeation flux indicating the necessity of PG. However, the formulation V2 
showed to be the most effective delivery. The presence of DMSO, PG and higher percentage of 
EtOH compared to V1 formulation, improved drug solubility and changed the thermodynamic 
activity of valsartan. The solubility of valsartan in stratum corneum was improved and this 
caused an overall improvement in permeation behavior of valsartan across the human skin. It is 
likely that these conventional chemical enhancers disrupt the highly ordered bilayer structures of 
the intracellular lipids found in stratum corneum by inserting amphiphilic molecules into these 
bilayers to disorganize molecular packing.  
 
In vitro evaluation of Losartan potassium 
 There are several publications in the literature demonstrating that molecules in neutral 
form have better permeation rates compared to charged molecules in transdermal transport [54].  
Human skin is hydrophobic and the salt from the original drug molecule has poor permeability 
across the skin as compared to its neutral or base form. However in this study we have chosen 
losartan potassium, as the best candidate to be tested. Losartan potassium yielded additional 
advances compared to neutral form. In particular the salt form is soluble in water which was used 
as a solvent in the formulations tested. In addition, losartan potassium is the active 
pharmaceutical ingredient that has been used in numerous transdermal patches designed and 
demonstrated in the literature [55-57].  
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 Losartan potassium is freely soluble in water with oral bioavailability of 33 % due to first 
pass metabolism in liver. It is also soluble in alcohols. All produced formulations of losartan 
potassium contained water and EtOH as main solvents in equal proportions. EtOH was also used 
to enhance penetration. DMSO was avoided to be used in high concentrations in the prepared 
formulations due to the known toxic side effects. The potential advantage was that the produced 
formulations did not have any pathological effects on the skin. The formulations L3 and L4 
(solvents and IPM and PG respectively), were the guide to modify and produce improved 
formulation consisted of a mixture of IPM and PG. According to the analysis the formulation L1 
showed the best permeation, which appears to be twice as high compared to formulations L2 and 
L5. The presence of TCL in formulation L1, -not in the other formulations- indicates the 
importance of this ingredient for enhancing permeability and showing a constant release profile. 
It seems that the lipophilic alkyl chain length of TCL is an important parameter in the promotion 
of penetration enhancement. It is reported that the lipid layers of stratum corneum play a 
significant role in skin permeation for lipophilic drugs. 
 
In vivo studies for valsartan and losartan potassium 
 The antihypertensive effect of transdermal administration of valsartan and losartan 
potassium were evaluated in Wistar rats. Animals treated with formulations V2 (valsartan) and 
L1 (losartan), showed a significant decreased in MABP even after 24 hours of administration. 
Transdermal delivery is a “slow intravenous infusion” with 100 % bioavailability. Findings from 
the in vivo studies indicated that both sartans had the ability to penetrate through rat skin. A 
therapeutic response was achieved 3 hours after administration. Furthermore, no skin irritation 
was observed in both cases which indicated that these particular formulations could be used for 
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further development. V2 significantly lowered blood pressure as early as 3 hours which remained 
until 24 hours and L1 was shown to lower blood pressure induced by ANGII as early as 3 hours 
although not significant, which was further decreased and showed significance by 24 hours.  
 
In vitro studies for the mechanism of AT1 receptor blockade 
 As blocking the AT1 receptor results in beneficial antihypertensive effects, we used rabbit 
interlobar arteries to determine if other vasodilators could be involved in this hypotensive effect. 
It is well established that the endothelium layer of arteries plays a major role in exerting 
beneficial effects such as vasodilation via releasing  nitric oxide [58], suggesting that 
candesartan, losartan and valsartan as AT1 receptor blockers, could cause the release of nitric 
oxide in order to induce vasodilation to exhibit antihypertensive effects. However, in our present 
study we have shown that upon AT1 receptor blockade, the vasodilative effect of the RAS 
heptapeptide, alamandine, is revealed within renal interlobar arteries. However, in animals that 
respond poorly to angII, such as rat aorta, alamandine is not a vasoconstrictor but instead a 
vasodilator [36], supporting our results [59, 60]. Interestingly, in rabbit aorta, we have shown 
that alamandine does not constrict nor dilate rabbit aorta (unpublished observation), but does 
enhance ACh mediated vasodilation [35], demonstrating that each vascular bed could respond 
differently to peptides.        
 The vasodilatory beneficial antihypertensive effect of alamandine is due to its structural 
features, which are in line with our previous studies about the role and importance of 
phenylalanine aromatic amino acid at position 8 triggering agonist activity [26, 27, 29, 61, 62]. 
Structure activity studies on Angiotensin analogues have shown that replacement of the Phe 
aromatic residue at position 8 with an aliphatic amino acid such as Ile, results in an antagonist 
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peptide with antihypertensive activity. Deletion of the Phe residue at position 8 of the 
octapeptide ANG II results in the novel RAS heptapeptide Alamandine, as well as Aspartic Acid  
at position 1 replaced by Alanine. Both modifications, replacements of Phe at position 8 with an 
aliphatic amino acid or deletion of the Phe, amino acid result in peptides with antagonists 
antihypertensive vasodilatory effects. Biological effects are in line with the documented evidence 
that the Phe amino acid in position 8 is critical for agonist hypertensive activity.  Our laboratory 
has been engaged for many years in the conformation analysis study of ANGII. Its superagonist 
[Sar1] ANGII in DMSO supports a bioactive conformation characterized by (a) a Tyr4-Ile5-His6 
bend, (b) a major His6-Pro7 trans conformer, (c) a cluster of the side chain aromatic rings of the 
triad key amino acids Tyr4, His6, Phe8, which drives the formation of the charge relay system 
between Tyr4 Hydroxyl, His6 imidazole and Phe8 carboxylate, analogues to that found in serine 
proteases. This relay system appears to be responsible for ANGII and [Sar1] ANGII biological 
activity. Disruption of this system, which occurs upon the replacement of the Phe ring with an 
aliphatic or deletion of the Phe amino acid in Angiotensin, results in antagonists antihypertensive 
beneficial effect as in the case of alamandine. Alamandine is a novel peptide of the RAS system 
and evidence is accumulating to show a vasodilatory beneficial effect. 
 
CONCLUSION 
 In summary, we demonstrated the effect of various formulations of the transdermal 
delivery of valsartan and losartan potassium. The formulations V2 and L1 for valsartan and 
losartan potassium respectively have great potential of transdermal administration, promising an 
alternative and more effective therapy in the treatment of hypertension. Moreover the results 
indicate a controlled delivery rate through the skin suggesting potential for conversion to a 
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matrix system. Results also indicate that another possible mechanism by which AT1 blockade 
exerts its vasodilatory/hypotensive effects is through the vasodilatory effect of alamandine in the 
kidney. 
 In conclusion, transdermal administration of sartans could be a feasible alternative route 
for prolonged hypertensive therapy, acting via ANGII type 1 receptor blockade and alamandine 
vasodilation.  
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FIGURE LEGENDS 
Scheme (1). Schematic representation of (A) angiotensin II (ANGII) and losartan, and, (B) 
alamandine and losartan. 
 
Fig. (1). In vitro diffusion of valsartan versus time in hours, using franz diffusion cells and full-
thickness human skin. Each point and data represents the mean ± standard error of the mean 
(SEM) of 6 replicates. * = p < 0.05,** = p < 0.01, *** = p < 0.001, **** = p < 0.0001, ns = no 
significance. Statistics shown in each are for V2 compared to V1, V3, V4, V5. 
 
Fig. (2). In vitro diffusion of losartan versus time in hours, using franz diffusion cells and full-
thickness human skin. Each point and data represents the mean ± standard error of the mean 
(SEM) of 6 replicates. * = p < 0.05,** = p < 0.01, *** = p < 0.001, **** = p < 0.0001, ns = no 
significance. Statistics shown in each are for L1 compared to L2, L3, L4, L5. 
 
 
Fig. (3). Mean arterial blood pressure (MABP) of Wistar rats (n=6/group), showing normal 
MABP, the increase of MABP after ANG II administration (ANGII) and the MABP after 3, 6, 8 
and 24 h of sartan transdermal administration. Each point and data represents the mean ± 
standard deviation (SD) of n=6 rats.  * = p < 0.05,** = p < 0.01, *** = p < 0.001, **** = p < 
0.0001, ns = no significance (upper statistics losartan compared to ANGII control, lower 
statistics valsartan compared to ANGII control). 
 
Fig. (4). (A) Blocking the AT1 R in in vitro reveals the vasodilative effect of alamandine in 
rabbit resistant arteries (interlobar). (B) Real time traces of alamandine dose response curve (in 
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green) and in candesartan incubated interlobar rings (red) after phenylephrine constrictions. ACh 
demonstrates that the endothelium was intact and therefore the blood vessels were functional. 
Each point and data represents the mean ± standard error of the mean (SEM) of n=3 rabbits.  * = 
p < 0.05,** = p < 0.01, *** = p < 0.001, **** = p < 0.0001, ns = no significance 
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Scheme (1). 
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Fig. (1). 
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Fig. (2). 
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Fig. (3). 
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Fig. (4).  
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Table 1 
Composition of valsartan and losartan formulations 
 
A Formulations 
 % w/w g 
Ingredients  V1 V2 V3 V4 V5 V1 V2 V3 V4 V5 
Valsartan 25 25 25 25 25 0.625 0.625 0.625 0.625 0.625 
EtOH 25 30 30 25 30 0.625 0.750 0.750 0.625 0.750 
PG - 30 - 50 10 - 0.750 - 1.250 0.250 
TCL - - 30 - - - - 0.750 - - 
IPM 50 10 10 - 30 1.250 0.250 0.250 - 0.750 
DMSO - 5 5 - 5 - 0.125 0.125 - 0.125 
Batch Size 100 100 100 100 100 2.5 2.5 2.5 2.5 2.5 
 
 
 
 
Table 2  
Inter-day slopes, intercepts and square correlation coefficients (r2) of calibration curves (n=3) 
 
 Slope Intercept r
2 
Valsartan Losartan Valsartan Losartan Valsartan Losartan 
1 0.9376 1.1313 0.0267 0.0114 0.9984 0.9997 
2 1.0143 1.1022 0.0079 0.0045 0.9995 0.9994 
3 0.9723 1.0534 0.0071 0.0220 0.9999 0.9994 
 
 
 
B Formulations 
 % w/w g 
Ingredients  L1 L2 L3 L4 L5 L1 L2 L3 L4 L5 
Losartan 25 25 25 25 25 0.6250 0.6250 0.6250 0.6250 0.6250 
EtOH 11.5 11.5 11.5 11.5 11.5 0.2875 0.2875 0.2875 0.2875 0.2875 
PG 5 5 - 43.57 21.78 0.1250 0.1250 - 1.0893 0.5445 
TCL 5 - - - - 0.1250 - - - - 
IPM 33.57 38.57 43.57 - 21.78 0.8393 0.9643 1.0893 - 0.5445 
H2O 19.93 19.93 19.93 19.93 19.93 0.4983 0.4983 0.4983 0.4983 0.4983 
Batch Size 100 100 100 100 100 2.5 2.5 2.5 2.5 2.5 
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Table 3 
Precision (% RSD) and accuracy (% RE) data for valsartan and losartan 
 
 
 
Table 4  
Effects of penetration enhancers on the permeation of valsartan and losartan 
 
Formulations Flux [μg/(cm2*h)] Lag Time (h) 
V1 0.3774 1.0029 
V2 0.5024 5.9960 
V3 0.0445 2.3656 
V4 0.0097 5.5077 
V5 0.0241 2.1073 
L1 0.2652 5.2518 
L2 0.1080 5.8099 
L3 0.0225 5.6345 
L4 0.0656 4.2871 
L5 0.0999 4.3721 
 
Actual 
concentration 
Detected concentration 
(mean ± SD, n=4) % RSD % RE 
Valsartan Intra-day 
8 μg/ml 7.59±0.13 1.68 -5.14 
90 μg/ml 87.74±1.13 1.28 -2.51 
160 μg/ml 159.29±2.31 1.45 -0.44 
 Inter-day 
8 μg/ml 8.07±0.82 10.16 0.92 
90 μg/ml 86.93±1.31 1.50 -3.41 
160 μg/ml 166.60±10.43 6.26 4.13 
    
Losartan  Intra-day 
8 μg/ml 8.37±0.12 1.41 4.64 
90 μg/ml 84.74±0.65 0.77 -5.84 
160 μg/ml 153.97±1.82 1.18 -3.77 
 Inter-day 
8 μg/ml 7.94±0.37 4.67 -0.71 
90 μg/ml 83.67±1.91 2.28 -7.03 
160 μg/ml 156.97±5.00 3.18 -1.89 
